reason report
strong retain benefit bring bard one step closer aa pt
bottom line see posit cardin data pave
way substanti opp ty alport syndrom also de-risk
even larger opp ty autosom domin polycyst kidney diseas
adpkd current recal bardoxolon bard hit
primari key secondari endpoint cardin trial
combin favor safeti profil high chanc
receiv regulatori approv view end remind
investor reacquir right op link bard
improv econom moreov similar trial design
durat endpoint leverag across multipl rare
form chronic kidney diseas ckd like render futur program
de-risk -- may materi next
on-going falcon trial result bard de-risk profil
alport syndrom adpkd pt increas vs
cardin hit primari secondari endpoint de-risk
regulatori standpoint recal trial compar estim
glomerular filtrat egfr measur week week
off-treat week time point bard cohort
demonstr superior egfr pbo -adjust valu ml/min
week ml/min week similar
jynarqu otsuka adpkd regulatori approv process fda
provid written guidanc analysi retain
egfr demonstr improv vs pbo yr treatment
may support acceler approv aa similar data yr
may support full approv sinc top-line result captur first yr
robust data suggest us bard one step closer gain
regulatori approv ahead yr data
magnitud retain benefit robust remark consist
view robust pbo -adjust egfr week indic
therapeut benefit -- halt declin kidney function toward
dialysi transplant -- clinic meaning management note
function declin may rapid alport syndrom particularli
refer absolut chang egfr week
howev importantli note consist bard effect across
variou form ckd irrespect underli diseas fact
rel egfr differ ml/min on- week off-
treatment week suggest bard treatment posit affect
cours diseas lastli note subgroup analysi highlight
similar efficaci time point across variou subgroup includ
among pediatr pt -- known progress rapidli
bardoxolon pt improv egfr versu placebo pt
worsen egfr believ benefit impress
compani inform svb leerink llc research
revenu mm ep present
net debt total capit
year price history/av daili volume mil
pleas refer page import disclosur price chart analyst certif
retain benefit profil appear robust jynarqu
otsuka hyperfiltr issu also concern repris
benefit ml/min pbo ml/min tolvaptan
ml/min arm show declin baselin contrast
cardin show robust pbo -adjust retain egfr benefit
ml/min bard show nonstatist decreas baselin
ml/min magnitud benefit higher
tolvaptan think bard compel efficaci profil alport
syndrom addit off-treat egfr higher bard
arm vs pbo arm disput notion bard drive
hyperfiltr combin recent data report american
societi nephrolog kidney week link believ
academ collabor effect quiet concern
hyperfiltr preclin model human believ fact
absolut egfr retain benefit end slightli neg
ml/min reflect rapid rate kidney diseas progress
patient children encourag
retain benefit vs placebo larger phase
rang benefit seen studi bardoxolon
report across bard pbo arm greater incid
seriou advers event sae seen pbo bard arm
notabl individu ae contribut discontinu
delta discontinu treatment arm small
encouragingli fluid overload major advers cardiac
event bard arm overal low rate cardiac vascular
reduc bard arm support bard favor safeti
profil lend addit evid hyperfiltr fault
model updat today confer call delv
cardin yr result also updat model
reflect financi result given read-through bard alport
syndrom program futur ckd program -- falcon studi
adpkd on-going -- see cardin result de-risk
futur program odd success consequ maintain
probabl alport increas probabl adpkd
previous
rate reata share outperform clinical-stag biopharmaceut compani
dedic develop commerci novel therapi aim rectifi
life-threaten metabol diseas current approv treatment
compani two lead compound bardoxolon methyl bard omaveloxolon omav
small molecul activ import protein involv maintain mitochondri
function reduc oxid stress resolv inflamm via suppress nf-kb
enthusiast metabol approach therapi fundament natur afford
potenti pursu extens therapeut portfolio current cover eight area
diseas enrol patient proof-of-concept studi potenti pivot
across sever target rare diseas believ potenti gener posit
data therebi advanc compani develop profil de-risk invest
charact stock encourag safeti learn extens previou
develop work bard may enabl strong therapeut profil achiev
multipl larg market opportun ripe innov bardoxolon studi
catalyst trial treatment connect tissu disease-associ pulmonari arteri
hypertens ctd-pah previous demonstr abil improv walk
distanc baselin key function measur diseas progress patient
popul suggest potenti superior current approv therapi vasodilatori
ctd-pah account pah patient repres opportun gain meaning
market share crowd pah market addit catalyst view compani
rare renal franchis compos alport syndrom autosom domin polycyst kidney
diseas adpkd low-risk/high-reward strategi bardoxolon view consist
benefit seen part phase moxi trial omaveloxolon friedreich ataxia
fa program promis indic omav potenti rectifi function neurolog
deterior symptomat fa beyond three lead program longer term upsid could come
progress pipelin focus mitochondri myopathi pulmonari hypertension-ild
melanoma rare kidney diseas orphan neurolog indic
rate share outperform pt leverag proprietari
target therapi bard omav develop novel therapeut patient rare
life-threaten diseas caus dysregul metabol mitochondri function
reta program seek either improv upon current standard care ctd-pah
becom first-to-market therapi diseas approv therapi exist alport
syndrom friedreich ataxia fa mitochondri myopathi conserv project
probabl success po bard ctd-pah due advanc follow
rel small phase residu uncertainti surround mechan
action appropri patient popul howev believ catalyst trial
highli power alport syndrom ascrib po bard base highli
encourag cardin data extens clinic histori increas estim glomerular
filtrat rate egfr singl endpoint approv ascrib po omav fa
follow posit part moxi data could registr base posit ph
phoenix data includ model assign po well
po adkpkd po lgan bardoxolon model assign credit
program potenti revenu gener collabor reta pipelin
multipl innov product routin seen clinic stage biotechnolog compani
result develop regulatori market reimburs uncertainti believ
share best valu via dcf analysi use discount rate termin
growth rate yield pt
pre-commerci stage compani risk valuat includ clinic trial outcom delay
clinic develop regulatori risk prior approv reimburs risk post-approv
also sinc bardoxolon omaveloxolon first-in-class therapi unforeseen complic
risk may emerg financi perspect clinic develop requir signific
invest could necessit dilut financ road
 except ep
total incom expens
equival
chang cash
receiv collabor arrang
prepaid expens current asset
accru direct research current liabil
proce long-term debt
pymnt defer disc issuanc cost
proce stock offer
payment defer offer cost
debt pay
proce sharehold promissori note
exercis option
payment capit leas
autoimmun inflammatori disord
safeti pk
